AsPC1细胞

AsPC-1/AsPC-1细胞系/AsPC-1细胞株/AsPC-1人胰腺癌细胞Cell line name AsPC-1

Synonyms AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1

Accession CVCL_0152

Resource Identification Initiative To cite this cell line use: AsPC-1 (RRID:CVCL_0152)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: KuDOS 95 cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: NCI RAS program mutant KRAS cell line panel.

Population: Caucasian.

Doubling time: ~38-40 hours (PubMed=7182348); 46 hours (PubMed=25984343).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Metabolome analysis.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: Proteome analysis by 2D-DE/MS.

Omics: shRNA library screening.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814.

Misspelling: ASPC; GEO=GSM383935.

Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.

PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940

Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T., Real F.X.

Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.

Am. J. Pathol. 153:201-212(1998)

 

PubMed=10027410; DOI=10.1016/S0002-9440(10)65298-4; PMCID=PMC1850008

Ghadimi B.M., Schrock E., Walker R.L., Wangsa D., Jauho A., Meltzer P.S., Ried T.

Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas.

Am. J. Pathol. 154:525-536(1999)

 

PubMed=10408907; DOI=10.1016/S0304-3835(98)00380-2

Bartsch D.K., Barth P., Bastian D., Ramaswamy A., Gerdes B., Chaloupka B., Deiss Y., Simon B., Schudy A.

Higher frequency of DPC4/Smad4 alterations in pancreatic cancer cell lines than in primary pancreatic adenocarcinomas.

Cancer Lett. 139:43-49(1999)

 

PubMed=11115575; DOI=10.3892/or.8.1.89

Sun C.-L., Yamato T., Furukawa T., Ohnishi Y., Kijima H., Horii A.

Characterization of the mutations of the K-ras, p53, p16, and SMAD4 genes in 15 human pancreatic cancer cell lines.

Oncol. Rep. 8:89-92(2001)

 

PubMed=11169959; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1049>3.0.CO;2-C

Sirivatanauksorn V., Sirivatanauksorn Y., Gorman P.A., Davidson J.M., Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.

Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.

Int. J. Cancer 91:350-358(2001)

 

PubMed=11787853; DOI=10.1007/s004280100474

Moore P.S., Sipos B., Orlandini S., Sorio C., Real F.X., Lemoine N.R., Gress T.M., Bassi C., Kloppel G., Kalthoff H., Ungefroren H., Lohr J.-M., Scarpa A.

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Virchows Arch. 439:798-802(2001)

 

PubMed=12692724; DOI=10.1007/s00428-003-0784-4

Sipos B., Moser S., Kalthoff H., Torok V., Lohr J.-M., Kloppel G.

A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform.

Virchows Arch. 442:444-452(2003)

 

PubMed=14695172

Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L.-C., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M.G., Hruban R.H.

Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies.

Cancer Res. 63:8614-8622(2003)

 

PubMed=15126341; DOI=10.1158/0008-5472.CAN-03-3159

Heidenblad M., Schoenmakers E.F.P.M., Jonson T., Gorunova L., Veltman J.A., van Kessel A.G., Hoglund M.

Genome-wide array-based comparative genomic hybridization reveals multiple amplification targets and novel homozygous deletions in pancreatic carcinoma cell lines.

Cancer Res. 64:3052-3059(2004)

 

PubMed=15367885; DOI=10.1097/00006676-200410000-00004

Loukopoulos P., Kanetaka K., Takamura M., Shibata T., Sakamoto M., Hirohashi S.

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Pancreas 29:193-203(2004)

 

PubMed=15688027; DOI=10.1038/sj.onc.1208383

Heidenblad M., Lindgren D., Veltman J.A., Jonson T., Mahlamaki E.H., Gorunova L., van Kessel A.G., Schoenmakers E.F.P.M., Hoglund M.

Microarray analyses reveal strong influence of DNA copy number alterations on the transcriptional patterns in pancreatic cancer: implications for the interpretation of genomic amplifications.

Oncogene 24:1794-1801(2005)

 

PubMed=15770730; DOI=10.3748/wjg.v11.i10.1521; PMCID=PMC4305696

Ma J.-H., Patrut E., Schmidt J., Knaebel H.-P., Buchler M.W., Marten A.

Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.

World J. Gastroenterol. 11:1521-1528(2005)